Tarao K, Nozaki A, Chuma M, Taguri M, Maeda S. Effectiveness of entecavir in preventing hepatocellular carcinoma development is genotype-dependent in hepatitis B virus-associated liver cirrhosis. World J Hepatol 2021; 13(1): 144-150 [PMID: 33584993 DOI: 10.4254/wjh.v13.i1.144]
Corresponding Author of This Article
Kazuo Tarao, MD, PhD, Director, Department of Gastroenterology, Tarao’s Gastroenterological Clinic, 2-58-6, Taiyo Building Futamatagawa, Asahi-ku, Yokohama 241-0821, Japan. duoluoweih7@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Kazuo Tarao, Department of Gastroenterology, Tarao’s Gastroenterological Clinic, Yokohama City 241-0821, Japan
Akito Nozaki, Makoto Chuma, Gastroenterological Center, Yokohama City University Medical Center, Yokohama 232-0024, Japan
Masataka Taguri, Department of Data Science, Yokohama City University School of Data Science, Yokohama 236-0004, Japan
Shin Maeda, Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan
Author contributions: Tarao K summarized the data and wrote the paper; Nozaki A, Chuma M, and Maeda S were involved in the interpretation of data, and the development and critical revision of the manuscript for important intellectual content; Taguri M conducted the statistical analysis.
Supported bythe Kanagawa Association of Medical and Dental Practitioners.
Conflict-of-interest statement: Nozaki A has received research funding from Gilead Sciences and Abb Vie. Tarao K, Chuma M, Maeda S, Taguri M declare that they have no conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kazuo Tarao, MD, PhD, Director, Department of Gastroenterology, Tarao’s Gastroenterological Clinic, 2-58-6, Taiyo Building Futamatagawa, Asahi-ku, Yokohama 241-0821, Japan. duoluoweih7@gmail.com
Received: August 31, 2020 Peer-review started: August 31, 2020 First decision: November 3, 2020 Revised: November 16, 2020 Accepted: November 28, 2020 Article in press: November 28, 2020 Published online: January 27, 2021 Processing time: 148 Days and 9 Hours
ARTICLE HIGHLIGHTS
Research background
The oral nucleos(t)ide analogue, entecavir (ETV) was demonstrated to reduce the rate of hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV)-associated liver cirrhosis. However, the reduction in HCC is different in various countries of the world.
Research motivation
The relationship between the reduction of HCC and HBV genotypes is interesting.
Research objectives
We surveyed the differences in the reduction of HCC development following ETV administration in many countries.
Research methods
We surveyed the differences in the reduction of HCC development following long-term administration of ETV based on already published articles using PubMed (2004-2019).
Research results
The countries which showed the greatest reduction in HCC development following ETV administration were Spain, Canada, and most ineffective countries or regions were South Korea, China, Taiwan, and Hong Kong. With ETV administration, the incidence of HCC in genotype D regions was significantly lower than that in genotype C regions. The initial HBV-DNA levels in genotype C patients was almost the same as that in genotype D patients. No relationship was observed between the prevalence ratio of HBV and the incidence of HCC following ETV treatment.
Research conclusions
The effectiveness of ETV in preventing HCC development in HBV-associated liver cirrhosis is genotype-dependent.
Research perspectives
In countries with low effectiveness of ETV in the prevention of HCC development, frequent surveillance using imaging modalities will be necessary.